Polaryx Therapeutics (NASDAQ:PLYX) Releases Earnings Results

Polaryx Therapeutics (NASDAQ:PLYX) posted its quarterly earnings results on Friday. The company reported ($0.05) earnings per share (EPS) for the quarter, FiscalAI reports.

Polaryx Therapeutics Trading Down 21.7%

Shares of PLYX stock traded down $0.74 during midday trading on Friday, reaching $2.67. 313,076 shares of the company were exchanged, compared to its average volume of 1,592,900. Polaryx Therapeutics has a 12 month low of $2.20 and a 12 month high of $48.91. The business has a 50 day simple moving average of $5.35.

Analysts Set New Price Targets

PLYX has been the subject of several recent research reports. Maxim Group initiated coverage on Polaryx Therapeutics in a report on Friday, February 27th. They set a “buy” rating and a $10.00 target price for the company. Weiss Ratings initiated coverage on Polaryx Therapeutics in a report on Friday, April 24th. They set a “sell (e-)” rating for the company. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Polaryx Therapeutics has a consensus rating of “Hold” and an average price target of $10.00.

About Polaryx Therapeutics

We are a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”). Our therapeutic philosophy is centered on delivering safe, effective, and patient-friendly treatments that address the underlying pathophysiology of these catastrophic diseases and their significant unmet need. Our multi-modal approach integrates small molecule therapies, including a combination therapy, and a gene therapy, positioning us to potentially address both the genetic and downstream pathological features of LSDs.